This episode of "This Week in Parasitism" (TWIP) covers two distinct papers. First, the hosts discuss a brief clinical case report from the Journal of Travel Medicine documenting a viable Schistosoma mansoni infection in a patient 41 years after her last known exposure. The infection was discovered incidentally during a routine colonoscopy, setting a new record for the longest-known persistence of this parasite and highlighting its capacity for long-term, asymptomatic survival.
The main discussion focuses on a research article from Nature Communications detailing the development of a robust genetic screening platform for Cryptosporidium, a leading cause of severe diarrheal disease with limited treatment options. The researchers created an efficient, targeted CRISPR-Cas9 system to systematically knock out parasite genes and assess their importance for survival in vivo. After validating the method on the pyrimidine salvage pathway, they applied it to screen potential vaccine candidates. A key finding was the essential role of the protein CP23 in parasite fitness and reinfection. Contrary to previous assumptions, the study localized CP23 internally within the parasite's pellicle, not on its surface, and demonstrated that its loss impairs the parasite's gliding motility, a critical function for transmission within the host. This work provides powerful new tools for the field and identifies parasite motility as a promising therapeutic target.
TWIP 268: A Loyal Parasite and Unlocking Crypto's Secrets
A case report in the Journal of Travel Medicine describes a woman found to have a viable Schistosoma mansoni infection, discovered accidentally during a routine colonoscopy.
Her last potential exposure was a single swim in Lake Kivu, Rwanda, 41 years earlier.
Key Takeaway: This is the longest documented S. mansoni infection ever reported, demonstrating the remarkable ability of some parasites to persist silently in a host for decades.
0:16:09 Main Topic: The Challenge of Cryptosporidium
The hosts discuss a paper from Nature Communications aimed at understanding Cryptosporidium, a major cause of severe diarrhea, particularly in infants and the immunocompromised.
Current treatments, like nitazoxanide, are suboptimal, and there is no vaccine, creating an urgent need for new therapeutic targets.
0:24:09 Developing a CRISPR Toolkit for a Parasite
Researchers developed and optimized a targeted CRISPR-Cas9 system to efficiently edit genes in Cryptosporidium.
The parasite is an ideal candidate for this technology because its life cycle stages in the intestine are haploid, meaning there is only a single copy of each gene to disrupt.
The team first tested their CRISPR screen on genes involved in the pyrimidine salvage pathway, successfully identifying which ones were essential for parasite survival.
They confirmed these findings using a secondary, inducible knockout system (Cre-Lox) that allowed them to remove a gene at a specific time by adding the drug rapamycin.
With the platform validated, researchers used it to screen 11 previously identified vaccine candidates to determine if they were essential for the parasite's survival. A gene that is essential for fitness makes a good vaccine target.
The screen identified an antigen known as CP23 as being critical for parasite fitness. Knocking out the CP23 gene severely impaired parasite growth and its ability to reinfect new cells.
While previous studies suggested CP23 was a surface protein, this paper's advanced imaging techniques located it internally, within the parasite's pellicle (a membrane-like layer).
The loss of CP23 was shown to disrupt the parasite's "gliding motility," its method of movement, which is essential for it to spread and invade new host cells.
Key Takeaway: The development of this CRISPR platform is a major methodological advance that will accelerate the discovery of new drug and vaccine targets for cryptosporidiosis. The study confirms CP23 is a vital protein and highlights parasite motility as a key vulnerability to target with future therapies.